AWACC

ANNUAL WORKSHOP ON ADVANCED CLINICAL CARE - AIDS

Articles

Home

 

REGISTRATION FOR AWACC 2019 IS NOW OPEN.

29 - 30 AUGUST 2019

ELANGENI HOTEL DURBAN

 

Important Info

Background

Other Conferences

5 March 2019

Registration opens.

23 August 2019

Registration closes

 

29 & 30 August 2019

Conference Dates

 

Registration Fees is R4000

 

This annual workshop which started in 2007 has been held yearly .

The first workshop was a joint effort of the Centre for AIDS research (CFAR) of Harvard Medical school and McCord Hospital (MH) ,Durban South Africa.

 The workshop receives great acclaim from delegates for its relevance to the growing ART roll out programme in South Africa (SA).

 Learn more

 

Continuing Professional

Development

Please note that CPD points including ethics

points will be allocated for the conference.

 

 

 

      

Follow Us 

    

 

 

 


The conference secretariat for AWACC 2016 will be managed by the NPC - MEDICATE-AIDS.
The directors are committed to continue to engage with our partners to ensure the success of this premier CME activity in the clinical care of people living with HIV.


   
 

Partners

 

 

 

 

 

 

 

Register for AWACC 2019

29 & 30 August 2019 at Elangeni Hotel

Organisational Registration
Organisations wanting to register more than 1 delegate may download and complete the organisation registration form here.

Manual Registration
Individuals wanting to register manually may download and complete the manual registration form here. 
Individual can register online and send proof of payment to This email address is being protected from spambots. You need JavaScript enabled to view it.

 Online Registration
Online registration may be requested by filling all mandatory fields and submitting, for which, you will receive an automatic reply.
For registration to be confirmed, attach payment confirmation and submit online or send by fax to 0866512921 or scanned and emailed to This email address is being protected from spambots. You need JavaScript enabled to view it.

The registration fee TBA
Payment may be made into the following account.
Please ensure that payment confirmation is sent to This email address is being protected from spambots. You need JavaScript enabled to view it.

Registration queries contact  This email address is being protected from spambots. You need JavaScript enabled to view it.


Banking Details:

Bank: Standard Bank
Name of the Business Account: Medicate-Aids
Account Number : 303335106
Branch Code : 043826
Branch : Overport City
Reference: Surname, SA ID Number or foreign passport number

Accommodation:

Kindly note, delegates may make reference to the following when making their reservations at Elangeni Tsogo Sun via email or call in:

• Block Name - AWACC 2019 Free Sell

• Contract Number - 1353651

Note, should the guests book online,

They will not qualify for the preferential rate offered.

 

Should you experience any difficulty registering online. please email This email address is being protected from spambots. You need JavaScript enabled to view it. 

 

About

Background

This annual workshop which started in 2007 has been held yearly .The first workshop was a joint effort of the Centre for AIDS research (CFAR) of Harvard Medical school and McCord Hospital (MH) ,Durban South Africa.


Professor Bruce Walker and Dr Raj Gandhi from CFAR jointly arranged this with Dr. Henry Sunpath and Dr Helga Holst from MH. 130 delegates attended the workshop in 2007 at the Athlone Riverside hotel in Durban. The workshop received great acclaim from the delegates for its relevance to the growing ART roll out programme in South Africa (SA).


Aims:

The two-day interactive workshop will translate the latest evidence-based research and apply best practice models of care into good clinical practice, specifically for resource constrained areas


Objectives:

  1. Provide updates in the management of PLHIV with opportunistic infections, ART complications and treatment failure in resource-scarce settings.
  2. Educate on issues related to HIV in the pediatric population, the PMTCT programme and women.
  3. Develop experienced clinicians to work independently and serve as consultants in HIV medicine in different district and community health institutions, and
  4. create an opportunity for networking between HIV clinicians, academicians, researchers and policy makers.

Partnerships:

  1. Infectious Diseases Unit of the Nelson Mandela School of Medicine (NRMSM) at the University of KwaZulu-Natal (UKZN)
  2. The South African HIV Clinicians Society (SAHIVCS) and
  3. HIV-AIDS-STI-TB (HAST UNIT) OF THE KZN DEPARTMENT OF HEALTH (DOH).

Speakers:

All major local institutions involved in HIV care and research over the last 6 years : UKZN Health Sciences department, Centre for programme in AIDS research South Africa (CAPRISA), Hospice Palliative Care Society (HPCS-SA), University of Wits and Cape Town, Right to Care, Kwa Zulu Natal Research Institute of HIV and TB (K-RITH). Several speakers have participated from leading US universities yearly.


MEDICATE-AIDS Directors

  • Dr Henry Sunpath (MBBS; MFam Med; Dip HIVMan; MPH)
  • Mr. Nash Maharaj (NDM Accounting)
  • Dr. Christina Edwin (MBBS; DipHIVMan; MPhilPal Med)

The organizing committee:

  • Dr Henry Sunpath (chairperson)
  • Dr. Raj Gandhi (ID Unit Mass General Hospital, Harvard Medical School)
  • Prof MYS Moosa (ID Unit, NRMSM at UKZN)

Delegates:

The conference has attracted clinicians (nurses and doctors and pharmacists) from the private sector and public sector. Each year between 300 and 400 delegates have attended. Many medical aid administrators, pharmaceutical reps, heatlh department officials and paraclinical workers have also been part of the workshop.


List of the topics covered 2007 till 2015 will reflect the many challenges unique to the times from the initial ART roll out in SA to the current programme with about 2 million PLHIV on ART. The presentations are predominantly case based discussions.


  1. ART guidelines: when to start
  2. ART toxicities: management of lactic acidosis, peripheral neuropathy and lipodystrophy
  3. PMTCT guidelines: sd NVP and other regimens
  4. Paediatric ART challenges: treating younger children
  5. ART related anaemia
  6. Management of thrombocytopenia
  7. IRIS
  8. Renal failure in HIV
  9. Approach to CNS mass lesions
  10. Cryptococcal meningitis
  11. Challenges of a limited formulary in treating HBV infection
  12. Management of treatment failure: use of viral load monitoring
  13. Second line virological failures
  14. Adherence measures
  15. Role of traditional medicines
  16. HIV/TB and the liver
  17. Persistent diarrhea
  18. TB AND ART guidelines
  19. Hepatitis B treatment guidelines
  20. Tenofovir and renal failure
  21. New SA guidelines for treatment of pt with CD4 counts<350
  22. Early neurogognitive disorders
  23. When to start ART after OI diagnosis
  24. Operationalisation of inpatient ART
  25. Surgery in HIV patients
  26. Dermatological manifeatations
  27. Kaposis Sarcoma
  28. Revised PMTCT guidelines
  29. Metabolic complications of ART
  30. Genotypic resistance patterns of first and second line ART in SA
  31. Rheumatological manifestations in HIV
  32. Infection control in TB
  33. MDR and XDR TB
  34. Novel /pipeline TB drugs
  35. Rit Lopinavir and TB treatment
  36. Rapid diagnostics for TB
  37. Linkage to care in HIV
  38. Quality in Chronic disease management
  39. Management of immunological failure
  40. Palliative AIDS care
  41. Community based care for MDR/XDR TB
  42. NIMART
  43. Pharmacovigilance report
  44. Eradication of HIV/TB
  45. HIV in the ageing population
  46. Third line salvage ART
  47. Transmitted resistance
  48. Prevention of HIV: combined startegies
  49. Strengthening health systems
  50. Starting and sequencing ART
  51. Retention in care
  52. INH preventative therapy
  53. Expanding ART access
  54. Transmitted resistance
  55. Drug resistance workshops
  56. Workshops to reduce mortality among those presenting with advanced disease

PLANS FOR 2019 ONWARDS:


1.Continued partnerships with current partners and extension of participation from other Southern African clinicians


2.Case based presentations that encourage participation and extended question and answer sessions


3.Support for DOH programme to build capacity among clinicians to manage patients who still present in advanced clinical disease. To build capacity to manage patients who fail virologically and those who may need third line ART.


4.To support systems to get PLHIV to engagae in care early and identify early warning indicators for virological failure and provide timely intervention


5.To continue to use the feedback from delegates yearly to build an academic and clinical programme of teaching 
through workshops.